D
Denis Glotz
Researcher at French Institute of Health and Medical Research
Publications - 163
Citations - 9457
Denis Glotz is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 47, co-authored 149 publications receiving 8164 citations. Previous affiliations of Denis Glotz include Paris Diderot University.
Papers
More filters
Journal ArticleDOI
Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection.
Lorraine C. Racusen,Robert B. Colvin,Kim Solez,Michael J. Mihatsch,Philip F. Halloran,Patricia Campbell,Michael Cecka,Jean Pierre Cosyns,Anthony J. Demetris,Michael C. Fishbein,Agnes B. Fogo,Peter N. Furness,Ian W. Gibson,Denis Glotz,Pekka Häyry,Lawrence Hunsickern,Michael Kashgarian,Ronald H. Kerman,Alex J. Magil,Robert A. Montgomery,Kunio Morozumi,Volker Nickeleit,Parmjeet Randhawa,Heinz Regele,Daniel Serón,Surya V. Seshan,Stale Sund,Kiril Trpkov +27 more
TL;DR: This article presents international consensus criteria for and classification of AbAR developed based on discussions held at the Sixth Banff Conference on Allograft Pathology in 2001, to be revisited as additional data accumulate in this important area of renal transplantation.
Journal ArticleDOI
Complement-Binding Anti-HLA Antibodies and Kidney-Allograft Survival
Alexandre Loupy,Carmen Lefaucheur,Dewi Vernerey,Christof Prugger,Jean-Paul Duong Van Huyen,Nuala Mooney,Caroline Suberbielle,Véronique Frémeaux-Bacchi,Arnaud Mejean,François Desgrandchamps,Dany Anglicheau,Dominique Nochy,Dominique Charron,Jean-Philippe Empana,Michel Delahousse,Christophe Legendre,Denis Glotz,Gary S. Hill,Adriana Zeevi,Xavier Jouven +19 more
TL;DR: Assessment of the complement-binding capacity of donor-specific anti-HLA antibodies appears to be useful in identifying patients at high risk for kidney-allograft loss.
Journal ArticleDOI
Preexisting Donor-Specific HLA Antibodies Predict Outcome in Kidney Transplantation
Carmen Lefaucheur,Alexandre Loupy,Gary S. Hill,Joao Andrade,Dominique Nochy,Corinne Antoine,Chantal Gautreau,Dominique Charron,Denis Glotz,Caroline Suberbielle-Boissel +9 more
TL;DR: In conclusion, the risk for both AMR and graft loss directly correlates with peak HLA-DSA strength, which should help guide selection of acceptable grafts for sensitized patients.
Journal ArticleDOI
Antibody-mediated vascular rejection of kidney allografts: a population-based study
Carmen Lefaucheur,Alexandre Loupy,Dewi Vernerey,Jean-Paul Duong-Van-Huyen,Caroline Suberbielle,Dany Anglicheau,Jérôme Verine,T. Beuscart,Dominique Nochy,Patrick Bruneval,Dominique Charron,Michel Delahousse,Jean-Philippe Empana,Gary S. Hill,Denis Glotz,Christophe Legendre,Xavier Jouven +16 more
TL;DR: A type of kidney rejection not presently included in classifications: antibody-mediated vascular rejection is identified, which could lead to the development of new treatment strategies that could salvage many kidney allografts.
Journal ArticleDOI
Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection.
Carmen Lefaucheur,Dominique Nochy,J. Andrade,Jérôme Verine,C. Gautreau,Dominique Charron,Gary S. Hill,Denis Glotz,Caroline Suberbielle-Boissel +8 more
TL;DR: High dose IVIg alone is inferior to Plasmapheresis/IVIg/anti‐CD20/anti-CD20 as therapy for AMR and DSA postrejection can be quantified using solid phase assays, showing that 3 months after AMR, DSA levels are higher in patients with graft loss.